Autopsy report · NCT06332300

An Exploratory Clinical Study of Adebelimumab in Combination With Famitinib and Chemotherapy in Patients With NSCLC

“The study drug, Famitinib, was not marketed and the drug was not available.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Jiangsu Province Nanjing Brain Hospital

Sponsor type

University, hospital or other

Conditions

NSCLC

Interventions

Adebelimumab+Famitinib + FOLFIRI+Ariely

Participants

0

Sites

1

Countries

China

Trials that died the same way

• A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma
  “One of the drugs for the study is not commercially available.” (75% match in meaning)
• Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
  “Drug was not available.” (69% match in meaning)
• Iontophoresis in Psoriasis
  “FDA did not provide approval of the use of the drug for the study” (69% match in meaning)
• Topical Cannabidiol Cream and Post-exercise Recovery
  “The researchers were not able to acquire funding to initiate the study. Also, the study was not approved by the local IRB which requested a FDA new drug application.” (68% match in meaning)
• Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19
  “The study was not approved by the Italian Medicines Agency (AIFA).” (64% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.